NO20033042L - Cyklodekstrin-inneholdende farmasöytisk preparat - Google Patents

Cyklodekstrin-inneholdende farmasöytisk preparat

Info

Publication number
NO20033042L
NO20033042L NO20033042A NO20033042A NO20033042L NO 20033042 L NO20033042 L NO 20033042L NO 20033042 A NO20033042 A NO 20033042A NO 20033042 A NO20033042 A NO 20033042A NO 20033042 L NO20033042 L NO 20033042L
Authority
NO
Norway
Prior art keywords
cyclodextrin
pharmaceutical preparation
containing pharmaceutical
preparation
pharmaceutical
Prior art date
Application number
NO20033042A
Other languages
English (en)
Other versions
NO20033042D0 (no
Inventor
Norio Suzuki
Yukihiko Nagase
Hitoshi Yamauchi
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of NO20033042D0 publication Critical patent/NO20033042D0/no
Publication of NO20033042L publication Critical patent/NO20033042L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D293/00Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12Selenazoles; Hydrogenated selenazoles
NO20033042A 2001-01-04 2003-07-02 Cyklodekstrin-inneholdende farmasöytisk preparat NO20033042L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001000247 2001-01-04
JP2001016022 2001-01-24
PCT/JP2001/011048 WO2002055076A1 (fr) 2001-01-04 2001-12-17 Preparation pharmaceutique contenant de la cyclodextrine

Publications (2)

Publication Number Publication Date
NO20033042D0 NO20033042D0 (no) 2003-07-02
NO20033042L true NO20033042L (no) 2003-09-04

Family

ID=26607336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033042A NO20033042L (no) 2001-01-04 2003-07-02 Cyklodekstrin-inneholdende farmasöytisk preparat

Country Status (12)

Country Link
US (1) US20040053888A1 (no)
EP (1) EP1348432A4 (no)
JP (1) JPWO2002055076A1 (no)
KR (1) KR20030068203A (no)
CN (1) CN1492760A (no)
AR (1) AR032386A1 (no)
BR (1) BR0116658A (no)
CA (1) CA2434077A1 (no)
MX (1) MXPA03006071A (no)
NO (1) NO20033042L (no)
RU (1) RU2003119972A (no)
WO (1) WO2002055076A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368484A1 (en) 1999-03-31 2000-10-05 Daiichi Pharmaceutical Co., Ltd. Substrates for thioredoxin reductase
CN1853627B (zh) * 2005-04-25 2011-08-10 曾慧慧 双苯并异硒唑乙烷环糊精或环糊精衍生物包合物及其制备方法和其用途
JP5177429B2 (ja) 2005-07-18 2013-04-03 バイパー サイエンシズ,インコーポレイティド 癌の治療
JP4886233B2 (ja) * 2005-07-21 2012-02-29 独立行政法人物質・材料研究機構 エブセレンの可溶化方法
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
EP1795183B1 (en) * 2005-12-09 2009-07-15 Teva Pharmaceutical Industries, Inc. Aqueous dispersions and solutions of difficult to dissolve compounds and methods of their preparation
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
CN101522609A (zh) 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
US7994222B2 (en) 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
NZ579098A (en) * 2007-01-16 2012-07-27 Bipar Sciences Inc Formulations for cancer treatment
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
AR075239A1 (es) * 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder
RU2451680C1 (ru) * 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
CN107921046B (zh) 2015-06-12 2022-10-14 格林威治大学 作为干扰素-γ抑制剂的三嗪衍生物
WO2019002889A1 (en) 2017-06-30 2019-01-03 Industrial Technology Research Institute METHOD FOR TREATING AUTOIMMUNE NEUROLOGICAL DISEASE AND / OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULAS FOR LIQUID GALENIC FORM AND CONTROLLED RELEASE GALENIC FORM
WO2021054863A1 (ru) * 2019-09-18 2021-03-25 Рахимджан Ахметджанович РОЗИЕВ Стимулятор процессов репаративной регенерации тестикулярной ткани
WO2023240094A1 (en) * 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Amorphous dosage form containing ebselen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01131113A (ja) * 1987-08-27 1989-05-24 Dai Ichi Seiyaku Co Ltd 脳障害治療剤
US5288734A (en) * 1988-10-29 1994-02-22 A. Nattermann & Cie Gmbh Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
KR20010031520A (ko) * 1997-11-07 2001-04-16 스즈키 다다시 피페라진류-시클로덱스트린 복합체
AU1411600A (en) * 1998-11-30 2000-06-19 Sankyo Company Limited Immunoglobulin preparations

Also Published As

Publication number Publication date
NO20033042D0 (no) 2003-07-02
CN1492760A (zh) 2004-04-28
BR0116658A (pt) 2003-12-30
US20040053888A1 (en) 2004-03-18
AR032386A1 (es) 2003-11-05
CA2434077A1 (en) 2002-07-18
RU2003119972A (ru) 2004-12-27
EP1348432A4 (en) 2005-08-10
JPWO2002055076A1 (ja) 2004-05-13
MXPA03006071A (es) 2004-02-26
WO2002055076A1 (fr) 2002-07-18
KR20030068203A (ko) 2003-08-19
EP1348432A1 (en) 2003-10-01

Similar Documents

Publication Publication Date Title
NO20033143D0 (no) Farmasoytisk preparat
NO20030418D0 (no) Nytt farmasöytisk preparat
NO20033042L (no) Cyklodekstrin-inneholdende farmasöytisk preparat
FI20011478A (fi) Farmaseuttinen koostumus
NO20034026L (no) Nytt preparat
NO20033556L (no) Farmasöytiske formuleringer
EE200300416A (et) Ravimvorm
IS7051A (is) Lyfjasamsetningar
NO20035627D0 (no) Farmasöytisk formulering
NO20015149L (no) Nytt farmasöytisk preparat
NO20034695L (no) Nytt preparat
NO20025805L (no) Farmasöytisk preparat
NO20015148D0 (no) Nytt farmasöytisk preparat
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
NO20015104L (no) Nytt farmasöytisk preparat
NO20015105L (no) Nytt farmasöytisk preparat
DE10291905D2 (de) Pharmazeutische Zusammensetzung
NO20021036D0 (no) Farmasöytisk preparat
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE10107261B4 (de) Pharmazeutische Zusammensetzung
NO20041236L (no) Farmasoytisk formulering
FI5468U1 (fi) Farmaseuttinen koostumus
SE0103116D0 (sv) Pharmaceutical combination
SE0101326D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application